title: Statins in rheumatology.
abstract: Statins were developed for the treatment of lipid disorders and have been proved to reduce cardiovascular morbidity and mortality when used for primary or secondary prevention. Beneficial effects in patients with osteoporotic fractures or rheumatoid arthritis (RA) have been suggested but remain unproven. Cardiovascular morbidity and mortality are increased in patients with RA or systemic lupus erythematosus, who should undergo serum lipid assays. When these show dyslipidemia, statin therapy should be started according to current recommendations.
authors.affiliation: Rheumatology Department, G. Montpied Hospital, Place H. Dunant, BP 69, 63003 Clermont-Ferrand, France. msoubrier@chu-clermontferrand.fr
authors.forename: Martin
authors.initials: M
authors.lastname: Soubrier
authors.forename: Christian
authors.initials: C
authors.lastname: Roux
mesh_terms: D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D005598:Fractures, Spontaneous / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D012219:Rheumatology / Q000379:methods*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006903:Hydroxymethylglutaryl CoA Reductases